Here's What Analysts Are Forecasting For Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Results

Shareholders might have noticed that Redcare Pharmacy NV (ETR:RDC) filed its quarterly result this time last week. The early response was not positive, with shares down 7.0% to €61.40 in the past week. It was an okay result overall, with revenues coming in at €854m, roughly what the analysts had been expecting. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the current consensus from Redcare Pharmacy's nine analysts is for revenues of €3.41b in 2026. This would reflect a satisfactory 6.0% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 70% to €0.60. Yet prior to the latest earnings, the analysts had been forecasting revenues of €3.40b and losses of €0.72 per share in 2026. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a favorable reduction in losses per share in particular.

View our latest analysis for Redcare Pharmacy

There's been no major changes to the consensus price target of €86.00, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Redcare Pharmacy analyst has a price target of €115 per share, while the most pessimistic values it at €55.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Redcare Pharmacy's revenue growth is expected to slow, with the forecast 12% annualised growth rate until the end of 2026 being well below the historical 25% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 3.9% per year. So it's pretty clear that, while Redcare Pharmacy's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Redcare Pharmacy. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Redcare Pharmacy going out to 2028, and you can see them free on our platform here..

You should always think about risks though. Case in point, we've spotted 2 warning signs for Redcare Pharmacy you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.